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Randomized Clinical Trial
Gastrointestinal perforation in metastatic colorectal cancer 
patients with peritoneal metastases receiving bevacizumab
Abstract
AIM: To investigate the safety and efficacy of adding 
bevacizumab to first-line chemotherapy in metastatic 
colorectal cancer patients with peritoneal disease.
METHODS: We compared rates of gastrointestinal 
perforation in patients with metastatic colorectal cancer 
and peritoneal disease receiving first-line chemotherapy 
with and without bevacizumab in three distinct 
cohorts: (1) the AGITG MAX trial (Phase Ⅲ randomised 
clinical trial comparing capecitabine vs  capecitabine 
and bevacizumab vs  capecitabine, bevacizumab 
and mitomycinC); (2) the prospective Treatment of 
Recurrent and Advanced Colorectal Cancer (TRACC) 
registry (any first-line regimen ± bevacizumab); and 
(3) two cancer centres in New South Wales, Australia 
[Macarthur Cancer Therapy Centre and Liverpool 
Cancer Therapy Centre (NSWCC) from January 2005 to 
Decenber 2012, (any first-line regimen ± bevacizumab). 
For the AGITG MAX trial capecitabine was compared 
to the other two arms (capecitabine/bevacizumab 
and capecitabine/bevacizumab/mitomycinC). In the 
AGITG MAX trial and the TRACC registry rates of 
gastrointestinal perforation were also collected in 
patients who did not have peritoneal metastases. 
Secondary endpoints included progression-free survival, 
chemotherapy duration, and overall survival. Time-to-
event outcomes were estimated using the Kaplan-Meier 
method and compared using the log-rank test. 
RESULTS: Eighty-four MAX, 179 TRACC and 69 
NSWCC patients had peritoneal disease. There were 
no gastrointestinal perforations recorded in either the 
MAX subgroup or the NSWCC cohorts. Of the patients 
without peritoneal disease in the MAX trial, 4/300 
(1.3%) in the bevacizumab arms had gastrointestinal 
perforations compared to 1/123 (0.8%) in the 
capecitabine alone arm. In the TRACC registry 3/126 
(2.4%) patients who had received bevacizumab had a 
gastrointestinal perforation compared to 1/53 (1.9%) 
in the chemotherapy alone arm. In a further analysis 
of patients without peritoneal metastases in the TRACC 
registry, the rate of gastrointestinal perforations was 
9/369 (2.4%) in the chemotherapy/bevacizumab group 
and 5/177 (2.8%) in the chemotherapy alone group. 
The addition of bevacizumab to chemotherapy was 
associated with improved progression-free survival 
in all three cohorts: MAX 6.9 m vs  4.9 m, HR = 0.64 
(95%CI: 0.42-1.02); P  = 0.063; TRACC 9.1 m vs  5.5 m, 
HR = 0.61 (95%CI: 0.37-0.86); P  = 0.009; NSWCC 8.7 
m vs  6.8 m, HR = 0.75 (95%CI: 0.43-1.32); P  = 0.32. 
Chemotherapy duration was similar across the groups. 
CONCLUSION: Patients with peritoneal disease do 
not appear to have an increased risk of gastrointestinal 
perforations when receiving first-line therapy with 
bevacizumab compared to systemic therapy alone. 
Key words: Peritoneal neoplasms; Colorectal neoplasms; 
Bevacizumab; Intestinal perforation; Capecitabine
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Core tip: This report is an analysis of three prospective 
studies including a randomized clinical trial. We 
analysed the rates of gastrointestinal perforation 
in patients with metastatic colorectal cancer and 
peritoneal disease receiving bevacizumab and 
systemic therapy. Previous reports had raised concerns 
regarding the risk of gastrointestinal perforation in 
this population. Our reports suggest that the absolute 
risk is not elevated and in addition clinicians appear 
to be confident in using bevacizumab in patients 
with colorectal cancer and peritoneal disease. We 
recommend that the presence of peritoneal disease is 
not a contraindication to the use of bevacizumab and 
systemic therapy.
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INTRODUCTION
Peritoneal spread from colorectal cancer occurs in 
10%-15% of patients with metastatic colorectal 
cancer (mCRC)[1]. These patients typically have a high 
disease burden with increased morbidity and a worse 
prognosis than patients without peritoneal disease[2-4].
Gastrointestinal perforation is a well-documented 
side effect of bevacizumab, a humanized monoclonal 
antibody and occurs at a rate of 1%-2%. In the BRITE 
registry[5], 37 of 1953 metastatic colorectal patients 
had a gastrointestinal perforation. On multivariate 
analysis, risk factors associated with gastrointestinal 
perforation included intact primary tumour and prior 
adjuvant radiotherapy. The risk of gastrointestinal 
perforation may be enhanced in the presence of 
chemotherapy related gastrointestinal toxicity or by 
bevacizumab induced changes in tumour vasculature. 
A meta-analysis found gastrointestinal perforation 
occurs with the use of bevacizumab in other tumour 
types with the highest relative risk seen with intra-
abdominal cancers including colorectal, ovarian, 
pancreatic and renal cell cancers compared to breast, 
lung and glioblastoma[6]. 
The rates of gastrointestinal perforation in phase 
Ⅲ trials have been reported in ovarian cancer which 
like colorectal cancer has a predilection for peritoneal 
spread. In the OCEANS trial[7] and the AURELIA trial[8] 
the rate of gastrointestinal perforation was 0.8% and 
2.2% respectively, in patients receiving bevacizumab 
and chemotherapy. In a univariate analysis of patients 
receiving bevacizumab in the GOG 0218 trial[9]-
inflammatory bowel disease, small bowel surgery or 
large bowel surgery at time of primary resection was 
associated with an increased risk of gastrointestinal 
perforation. The increased risk of gastrointestinal 
perforation in patients with intra-abdominal tumours, 
bowel surgery or bowel obstruction have led some 
investigators to urge caution in using bevacizumab in 
patients with peritoneal metastases[6,10,11].
Our study aimed to assess the gastrointestinal 
safety outcomes of bevacizumab and systemic 
chemotherapy in mCRC patients with peritoneal 
disease in three cohorts, including both clinical trial and 
non-trial patients. The Australasian Gastrointestinal 
Trials Group (AGITG) MAX trial[12] included patients 
with peritoneal disease and hence was an ideal study 
for our analysis.
MATERIALS AND METHODS
Patient population
Adult patients with histological or radiological evidence 
of colorectal peritoneal metastases were identified 
from three sources: the AGITG MAX study[12], the 
TRACC registry (Treatment of Recurrent and Advanced 
Colorectal Cancer) and two community cancer centres 
in New South Wales, Australia (NSWCC).
AGITG MAX study
The MAX study was an international phase Ⅲ, open 
label, randomised clinical trial with three arms: (1) 
capecitabine; (2) capecitabine and bevacizumab; and 
(3) capecitabine, mitomycinC and bevacizumab. Data 
was collected prospectively in detailed case report 
forms and patients were recruited between July 2005 
and June 2007. Inclusion and exclusion criteria have 
been previously published[12].
TRACC registry
The TRACC registry is a multi-site prospective clinical 
registry established by BioGrid Australia in 2009 and 
supported by Roche Australia Pty Ltd. A consensus 
dataset, developed by a panel of clinicians, is used 
to capture comprehensive clinical, treatment and 
outcome data for consecutive patients with mCRC. 
Data are entered directly by clinicians into an electronic 
database[13]. Patient enrolment is ongoing at 24 sites 
across Australia. For this analysis, data was available 
from 16 sites.
NSWCC cohort
The NSWCC cohort was identified from two cancer 
centres in New South Wales - Macarthur Cancer 
Therapy Centre and Liverpool Cancer Therapy Centre. 
A search of the electronic medical records was 
performed to identify patients who had started any 
first line chemotherapy between January 2005 and 
December 2012. 
Data collection
Baseline information was collected including site of 
tumour, distribution of metastatic disease, height, 
weight, age, gender and performance status. 
Treatment information was collected: chemotherapy 
regimen, number of completed chemotherapy 
cycles (≥ 90% of each prescribed dose), abdominal 
adverse events of grade ≥ 2 occurring during first 
line treatment (abdominal pain, ascites, fistula, 
gastrointestinal perforations, gastrointestinal 
obstruction and tumour related haemorrhage) and 
CT assessments. Progression was determined by 
radiological or clinical progression using RECIST 1.0 
Criteria.
Statistical analysis
The primary endpoint of this analysis of all three 
cohorts was the rate of gastrointestinal perforation. 
Secondary endpoints included progression-free survival 
(PFS), duration of chemotherapy and overall survival 
(OS). PFS was defined as the time from baseline to 
progression or death. For all cohorts bevacizumab and 
chemotherapy was compared to chemotherapy alone. 
Toxicity and treatment duration were analysed 
by treatment received. Survival analyses were by 
intention-to-treat in the MAX trial and by treatment 
received in the other cohorts. Survival endpoints were 
analysed by Kaplan-Meier curves and compared using 
unadjusted log rank tests. The statistical methods of 
this study were reviewed by the biostatistician-Prof Val 
Gebski of the NHMRC Clinical Trials Centre. 
RESULTS
Patient population
In the MAX trial there were 84 patients with peritoneal 
disease with a median follow up of 30.8 mo. Thirty-
three received capecitabine alone and 51 received 
chemotherapy/bevacizumab. There were no significant 
clinicopathological differences between the two 
bevacizumab arms and the capecitabine arm. 
In the TRACC registry, 179 patients with peritoneal 
disease were identified with a median follow up of 26.3 
mo. Fifty-three patients had chemotherapy alone and 
126 patients had chemotherapy/bevacizumab. There 
were relevant differences in clinicopathological factors 
such as higher age, worse performance status, less 
use of doublet chemotherapy and more non- resected 
primaries in the chemotherapy alone arm (Table 1).
In the NSWCC patients there were 69 patients 
identified, 52 received chemotherapy alone and 17 
received chemotherapy/bevacizumab. In the NSWCC 
patients who received chemotherapy alone, 23/52 
(44.2%) had a documented relative contraindication 
to bevacizumab. Of those without a contraindication 
16/29 (55.2%) were treated with chemotherapy 
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Gastrointestinal perforations 
There were no gastrointestinal perforations recorded 
in either the MAX subgroup or the NSWCC cohorts. 
Of the patients without peritoneal disease in the MAX 
trial, 4/300 (1.3%) in the bevacizumab arms had 
gastrointestinal perforations compared to 1/123 (0.8%) 
in the capecitabine alone arm. In the TRACC registry 
3/126 (2.4%) patients who had received bevacizumab 
had a gastrointestinal perforation compared to 1/53 
(1.9%) in the chemotherapy alone arm. In a further 
analysis of patients without peritoneal metastases 
in the TRACC registry, the rate of gastrointestinal 
perforations was 9/369 (2.4%) in the chemotherapy/
bevacizumab group and 5/177 (2.8%) in the 
chemotherapy alone group (Figure 1). 
In the MAX trial 9/33 (27.3%) patients in the 
capecitabine arm had grade ≥ 2 diarrhoea compared 
to 21/51 (41.2%) in the two bevacizumab arms. There 
was one patient with tumour associated haemorrhage 
event in the capecitabine arm and one patient in the 
bevacizumab arms. 
alone prior to 2009 when bevacizumab was not 
publicly funded. Table 1 summarises the baseline 
characteristics. 
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Table 1  Baseline characteristics of all three cohorts
MAX TRACC NSWCC cohort
July 2005 to June 2007 July 2009 to June 2014 Jan 2005 to Dec 2012
Chemo alone Chemo + Bev Chemo alone Chemo + Bev Chemo alone Chemo + Bev
n 33 51 53 126 52 17
Age (yr)
   Median 70 67 72   64 66 60
   Range 47-84 39-83 31-91 30-87 38-83 21-79
Sex
   Male 15 30 22   71 35 11
   Female 18 21 31   55 17   6
ECOG
   PS 0 14 29   8   45 35 13
   PS 1 17 15 28   61 12   3
   PS 2   2   7 14   17   5   1
   PS 3 NA NA   3     3 NA NA
CCI NA NA
   0 33   89
   1-2 14   33
   ≥ 3   6     4
Primary site
   Colon 29 44 48 107 47 15
   Rectum   4   7   5   14   5   2
   Occult     5
Prior adjuvant Rx
   Yes   5 11 10   34 11   4
   No 28 40 43   92 41 13
Primary resected
   Yes 28 39 24   80 34 16
   No   5 12 29   46 18   1
No. of met sites NA NA
   1 15   30
   2 17   45
   ≥ 3 21   51
Chemo regimen NA NA
   Single-agent FP 19   12
   Oxaliplatin-based doublet 25   87
   Irinotecan-based doublet   6   18
   Single-agent Irinotecan   0     3
   Other   3     6
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Figure 1  Rate of gastrointestinal perforation.
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N/A: Not availiable; Chemo: Chemotherapy; Bev: Bevacizumab.
Survival outcomes
In the MAX trial median PFS was 6.9 mo in the two beva-
cizumab arms compared to 4.9 mo in the capecitabine 
alone arm with a HR = 0.64, (95%CI: 0.42-1.02); P = 
0.063 (Figure 2A). In the TRACC registry the median 
PFS was 9.1 mo in the chemotherapy/bevacizumab 
group compared to 5.5 mo in the chemotherapy alone 
group; HR = 0.61, (95%CI: 0.37-0.86); P = 0.009. 
In the NSWCC cohort the median PFS was 8.7 mo in 
the chemotherapy/bevacizumab group compared to 
6.8 mo in the chemotherapy alone group; HR = 0.75, 
(95%CI: 0.43-1.32); P = 0.32. 
In the MAX trial median OS was 14.3 mo in the 
two bevacizumab arms compared to 17.3 mo in the 
capecitabine alone arm; HR = 0.89, 95%CI: 0.55-1.45; 
P = 0.65 (Figure 2B). In the TRACC registry the median 
OS was 20.0 mo in the chemotherapy/bevacizumab 
group compared to 14.7 mo in the chemotherapy 
alone arm; HR = 0.60, 95%CI: 0.34-0.88; P = 0.013. 
In the NSWCC cohort the median OS was 23.4 mo in 
chemotherapy/bevacizumab group compared to 13.7 
mo in the chemotherapy alone group, HR = 0.62, 
95%CI: 0.33-1.17; P = 0.14.
In the MAX trial the median number of chemo-
therapy cycles in the two bevacizumab arms was 8 
cycles and 6 cycles in the capecitabine arm. In the 
NSWCC cohort the median duration of chemotherapy 
in the chemotherapy/bevacizumab group was 21 wk 
compared to 14 wk chemotherapy alone group.
DISCUSSION
Despite the advances in the treatment of metastatic 
colorectal cancer, the prognosis of patients with 
peritoneal disease remains poor. This analysis suggests 
that the addition of bevacizumab to chemotherapy 
does not increase the rate of gastrointestinal 
perforations in patients with metastatic colorectal 
cancer and peritoneal metastases. Specifically, 
no gastrointestinal perforations were seen in the 
patients with peritoneal disease in the MAX study 
and the NSWCC cohort, and in the TRACC registry 
bevacizumab use was not associated with an increased 
rate of gastrointestinal perforation. The addition of 
bevacizumab to standard first-line chemotherapy is 
associated with longer PFS in patients with peritoneal 
disease treated in the trial and non-trial settings. There 
was a consistent PFS benefit seen across studies, 
with the hazard ratios ranging from 0.61 to 0.75, with 
statistical significance only seen in the TRACC registry. 
However, the AGITG MAX clinical trial was not powered 
to detect statistically significant improvements in PFS 
within the peritoneal subgroup. Significant differences 
in prognostic variables, as well as selection bias 
may have led to the significant survival differences 
associated with bevacizumab use in the TRACC registry 
and the NSWCC cohort. Both the TRACC registry 
and NSWCC cohorts demonstrated a > 50% usage 
of bevacizumab alongside a range of chemotherapy 
regimens by clinicians. 
Multiple risk factors have been associated with 
an increased risk of gastrointestinal perforations. 
Intra-abdominal tumours such colorectal, ovarian, 
pancreatic and renal cell cancers have been associated 
with an elevated risk of gastrointestinal perforation 
compared to non-abdominal cancers such as breast 
and lung cancers[6,11]. In the BRITE registry[5] the 
rate of gastrointestinal perforation in all patients with 
mCRC was 1.9% with an elevated risk on multivariate 
analysis seen in patients with an intact primary tumour 
and prior adjuvant radiation. Given the increased risk 
of gastrointestinal perforations in patients with mCRC 
investigators have postulated various mechanisms 
including predisposing GI toxicity from chemotherapy, 
pelvic irradiation, intact primary tumour, peritoneal 
metastases and bevacizumab-induced changes in 
tumour vasculature. To our knowledge the risk of 
gastrointestinal perforation in patients with peritoneal 
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Figure 2  Progression-free survival (A) and overall survival (B) in the MAX trial patients with peritoneal disease: chemotherapy and bevacizumab vs 
chemotherapy alone. Chemo: Chemotherapy; Bev: Bevacizumab.
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disease has been poorly described. The AGITG MAX 
trial is the only randomised Phase Ⅲ trial comparing 
a bevacizumab containing arm to a non-bevacizumab 
containing arm where the outcomes of peritoneal 
disease patients are described. Although others 
have performed analyses of patients with peritoneal 
metastases in randomised trials, these were not 
comparisons of the addition of bevacizumab to 
chemotherapy[3,4,14]. In most cases safety analyses 
were not reported. 
Our analysis presents outcomes of patients in a 
clinical trial as well as outcomes in patients treated 
in typical community cancer centres. Rates of 
gastrointestinal perforations were available from all 
three cohorts and indicate that bevacizumab appears 
to be as safe in the peritoneal disease subgroup as 
compared to patients without peritoneal disease. 
Furthermore, despite previous series suggesting an 
elevated risk[6,10,11], clinicians appear to be comfortable 
in using bevacizumab in patients with peritoneal 
disease as reflected in the number of patients with 
peritoneal disease recruited to MAX and the proportion 
of bevacizumab-treated patients in the TRACC registry 
not being impacted by the presence or absence of 
peritoneal disease. The weaknesses of the analysis 
include the small patient numbers in each cohort. In 
Australia, bevacizumab has been publicly funded since 
2009 and thus the numbers of patients with peritoneal 
disease who had access to bevacizumab in the NSWCC 
were small. Nevertheless, this analysis represents 
the largest analysis of gastrointestinal perforations in 
patients with peritoneal disease.
There is significant discordance seen in the OS 
effects. The median OS in the MAX trial is longer in 
the capecitabine alone arm, however, the curves cross 
before and after the median with a HR = 0.89. Use 
of post-progression therapy was minimal in the MAX 
trial, suggesting imbalances in subsequent therapy 
do not explain the discordance between the impact 
on PFS and OS. Nonetheless, the OS findings of the 
subgroup of patients with peritoneal metastases are 
consistent with the overall MAX trial results. While a 
statistically significant improvement in OS was seen 
in the TRACC registry, this may be due to differences 
in prognostic factors between the bevacizumab and 
non-bevacizumab treated patients given the non-
randomised nature of the registry, which likely account 
for at least some of this gain. Such an imbalance in 
patient prognostic factors may also have explained the 
inconsistency in data from the BRITE registry[15], which 
showed a far larger survival gain with bevacizumab 
beyond progression in all patients with metastatic 
colorectal cancer than was seen in the randomised 
TML trial[16]. Although the difference in survival is large 
in the NSWCC cohort there are known significant 
baseline differences between the groups and these 
factors may account for the difference seen.
Alternative routes of bevacizumab administration 
may be helpful for patients with peritoneal disease, 
with case reports of intraperitoneal administration of 
bevacizumab with significant symptomatic benefit 
mainly in ovarian cancer patients[17-19]. However, we are 
unaware of any data related to the safety and efficacy 
of this approach in metastatic colorectal cancer. The 
results of ongoing trials are eagerly awaited[20].
In conclusion, this analysis of metastatic colorectal 
cancer patients with peritoneal disease reveals similar 
findings across a clinical trial and routine practice 
cohorts. The combination appears to be safe to 
use, without an increase in rate of gastrointestinal 
perforations observed in any of the cohorts. From our 
analysis, patients with metastatic colorectal cancer to 
the peritoneum should not be excluded from receiving 
bevacizumab.
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Bevacizumab is associated with gastrointestinal perforation with known risk 
factors such as intra-abdominal cancers, intact primary tumours and bowel 
obstruction. Initial use of bevacizumab in ovarian cancer was associated with 
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Research frontiers
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that the rate of gastrointestinal perforation in patients with metastatic colorectal 
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patients with metastatic colorectal cancer and peritoneal disease who do not 
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Gastrointestinal perforation includes perforation of the oesophagus, stomach, 
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